Simple indices of inflammation as predictors of death from cancer or cardiovascular disease in a prospective cohort after two decades of follow-up

QJM: An International Journal of Medicine

Volumn 104, Issue 5, 2011, Pages 387-394

  Godsland, I F ^a   North, B V ^a   Johnston, D G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CHOLESTEROL; GLOBULIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLADDER CANCER; BODY MASS; BRAIN CANCER; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGUS CANCER; EUROPEAN AMERICAN; EXERCISE; FACTORIAL ANALYSIS; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LEUKOCYTE COUNT; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SARCOMA; SCORING SYSTEM; SKIN CANCER; SMOKING; SPINDLE CELL SARCOMA; STOMACH CANCER; SURVIVAL TIME;

EID: 79955422846     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq213     Document Type: Article

References (37)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-95.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
3. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008; 659:15-30.
4. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132-40.
5. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799-809.
6. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998; 279:1477-82.
7. Danesh J, Collins R, Peto R, Lowe G. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analysis of prospective studies of coronary heart disease. Eur Heart J 2000; 21:515-20.
8. Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol 2003; 158:844-51.
9. HeikkiläK, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20:15-26.
10. Friedman GD, Fireman BH. The leukocyte count and cancer mortality. Am J Epidemiol 1991; 15:376-80.
11. Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985; 254:1932-7.
12. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch Intern Med 2006; 23:188-94.
13. Erlinger TP, Muntner P, Helzlsouer KJ. WBC Count and the Risk of Cancer Mortality in a National Sample of U.S. Adults: Results from the Second National Health and Nutrition Examination Survey Mortality Study. Cancer Epidemiol Biomarkers Prev 2004; 13:1052-6.
14. Jee SH, Park JY, Kim H-S, Lee TY, Samet JM. White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans. Am J Epidemiol 2005; 162:1062-9.
15. Shankar A, Mitchel lP, Rochtchina E, Wang JJ. The association between circulating white blood cell count, triglyceride level and cardiovascular and all-cause mortality: population-based cohort study. Atherosclerosis. 2007; 192:177-83.
16. Clarke R, Emberson JR, Breeze E, Casas JP, Parish S, Hingorani AD, et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med 2007; 167:1373-8.
17. Godsland IF, Leyva F, Worthington M, Walton C, Stevenson JC. Associations of smoking, alcohol and physical activity with risk factors for coronary heart disease and diabetes in the first follow-up cohort of the HDDRISC Study (HDDRISC-1). J Intern Med 1998; 244:33-41.
18. Leyva F, Godsland IF, Walton C, Worthington M, Stevenson JC. Factors of the metabolic syndrome - baseline interrelationships in the first follow-up cohort of the HDDRISC Study (HDDRISC-1). Arterioscler Throm Vasc Biol 1998; 18:208-14.
19. Lawlor DA, Ebrahim S, May M, Davey Smith G. (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol 2004; 159:1013-18.
20. Kay R. Treatment effects in competing-risks analysis of prostate cancer data. Biometrics 1980; 42:203-11.
21. Pintilie M. Competing Risks: a Practical Perspective. Chichester, Wiley, 2006.
22. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51:524-32.
23. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1997; 316:1236-8.
24. Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 1995; 44:369-74.
25. Engel LW, Strauchen JA, Chiazze L Jr, Heid M. Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular diseases. Am J Epidemiol 1980; 111:99-112.
26. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30.
27. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291:585-90.
28. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66:2483-7.
29. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 2006; 42:704-7.
30. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14:2413-8.
31. Borre M, Nerstrøm B, Overgaard J. Erythrocyte sedimentation rate-a predictor of malignant potential in early prostate cancer. Acta Oncol 1997; 36:689-94.
32. Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991; 114:361-5.
33. Chow B. The correlation between the albumin and alpha globulin contents of plasma. J Clin Invest 1947; 26:883-6.
34. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003; 417:3-11.
35. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990; 76:655-63.
36. Ropes MW, Rossmeisl E, Bauer W. The relationship between the erythrocyte sedimentation rate and the plasma proteins. J Clin Invest 1939; 18:791-8.
37. Oakley W. Erythrocyte sedimentation and the plasma fibrinogen. Lancet 1938; i:312.